Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 478.98% | 14.62% | -5.31% | -7.06% | 54.31% |
| Total Depreciation and Amortization | -0.74% | -2.79% | 0.63% | -0.12% | 0.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 147.08% | 0.00% | 6.82% | 8.19% | -27.27% |
| Change in Net Operating Assets | -2,084.91% | 128.20% | 73.91% | -3.72% | 150.64% |
| Cash from Operations | -5.60% | 44.11% | 62.93% | -10.32% | 30.61% |
| Capital Expenditure | 4.64% | 0.71% | -5.13% | -4.74% | -23.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -97.50% | -- | -- |
| Other Investing Activities | -111.59% | -65.22% | -1.25% | 67.07% | -213.64% |
| Cash from Investing | -5.10% | 6.31% | 62.65% | 8.01% | -30.38% |
| Total Debt Issued | -95.45% | -- | 22,000.00% | -- | 120.00% |
| Total Debt Repaid | 36.11% | 102.79% | -654.55% | -202.38% | -- |
| Issuance of Common Stock | -26.47% | 64.29% | -13.33% | 116.13% | -17.07% |
| Repurchase of Common Stock | -21.62% | -37,450.00% | 99.30% | 58.15% | 62.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.88% | -8.11% | -7.98% | -7.53% | -7.90% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.31% | 32.65% | 38.63% | 16.60% | -40.84% |
| Foreign Exchange rate Adjustments | -432.00% | 224.14% | 51.85% | -550.00% | -50.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.98% | 150.71% | 153.02% | 15.12% | -35.07% |
